Afficher la notice abrégée

Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation

dc.rights.licenseopenen_US
dc.contributor.authorDE WAAL, Renee
dc.contributor.authorWOOLS-KALOUSTIAN, Kara
dc.contributor.authorBRAZIER, Ellen
dc.contributor.authorALTHOFF, Keri N
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorJAQUET, Antoine
dc.contributor.authorDUDA, Stephany N
dc.contributor.authorKUMARASAMY, Nagalingeswaran
dc.contributor.authorSAVORY, Theodora
dc.contributor.authorBYAKWAGA, Helen
dc.contributor.authorMURENZI, Gad
dc.contributor.authorJUSTICE, Amy
dc.contributor.authorEKOUEVI, Didier K
dc.contributor.authorCESAR, Carina
dc.contributor.authorPASAYAN, Mark K U
dc.contributor.authorTHAWANI, Agness
dc.contributor.authorKASOZI, Charles
dc.contributor.authorBABAKAZO, Pelagie
dc.contributor.authorKARRIS, Maile
dc.contributor.authorMESSOU, Eugene
dc.contributor.authorCORTES, Claudia P
dc.contributor.authorKUNZEKWENYIKA, Cordelia
dc.contributor.authorCHOI, Jun Yong
dc.contributor.authorOWARWO, Noela C
dc.contributor.authorNIYONGABO, Annabelle
dc.contributor.authorMARCONI, Vincent C
dc.contributor.authorEZECHI, Oliver
dc.contributor.authorCASTILHO, Jessica L
dc.contributor.authorPETOUMENOS, Kathy
dc.contributor.authorJOHNSON, Leigh
dc.contributor.authorFORD, Nathan
dc.contributor.authorKASSANJEE, Reshma
dc.date.accessioned2024-12-13T09:32:23Z
dc.date.available2024-12-13T09:32:23Z
dc.date.issued2024-11-06
dc.identifier.issn1537-6591en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203917
dc.description.abstractEnBACKGROUND: While people with HIV (PWH) start antiretroviral treatment (ART) regardless of CD4 count, CD4 measurement remains crucial for detecting advanced HIV disease and evaluating ART programmes. We explored CD4 measurement (proportion of PWH with a CD4 result available) and prevalence of CD4 <200 cells/µL at ART initiation within the International epidemiology Databases to Evaluate AIDS (IeDEA) global collaboration. METHODS: We included PWH at participating ART programmes who first initiated ART at age 15-80 years during 2005-2019. We described proportions of PWH (i) with CD4 (measured within 6 months before to 2 weeks after ART initiation); and (ii) among those with a CD4, with CD4 <200; by year of ART initiation and region. RESULTS: We included 1,355,104 PWH from 42 countries in 7 regions; 63% were female. Median (interquartile range) age at ART initiation was 37 (31-44) in men and 32 (26-39) in women. CD4 measurement initially increased, or remained stable over time until around 2013, but then declined to low levels in some regions (Southern Africa, except South Africa: from 54 to 13%; East Africa 85 to 31%; Central Africa 72 to 20%; West Africa: 91 to 53%; and Latin America: 87 to 56%). Prevalence of CD4<200 declined over time in all regions, but plateaued after 2015 at ≥30%. CONCLUSIONS: CD4 measurement has declined sharply in recent years, especially in sub-Saharan Africa. Among those with a CD4, the prevalence of CD4 <200 remains concerningly high. Scaling up CD4 testing and securing adequate funding are urgent priorities.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enCD4 at ART start
dc.subject.enAdvanced HIV disease
dc.subject.enHIV care
dc.subject.enGlobal testing trends
dc.subject.enTreat-All
dc.title.enGlobal trends in CD4 count measurement and distribution at first antiretroviral treatment initiation
dc.title.alternativeClin Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/cid/ciae548en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39501773en_US
bordeaux.journalClinical Infectious Diseasesen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
bordeaux.identifier.funderIDNational Institutes of Healthen_US
hal.identifierhal-04835566
hal.version1
hal.date.transferred2024-12-13T09:32:27Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Clinical%20Infectious%20Diseases&amp;rft.date=2024-11-06&amp;rft.eissn=1537-6591&amp;rft.issn=1537-6591&amp;rft.au=DE%20WAAL,%20Renee&amp;WOOLS-KALOUSTIAN,%20Kara&amp;BRAZIER,%20Ellen&amp;ALTHOFF,%20Keri%20N&amp;JAQUET,%20Antoine&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_CID_2024_Waal.pdf
Taille:
538.5Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée